LexDanaLexDanabeta
Inventor

Wayne R. Kindsvogel

Inventor
Seattle, WA, US

Overview

102→
Patents
1991–2020
Patent span
Human necessities
Primary field (CPC A)

Patents· 102 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary
C07KPeptides25%
A61KPreparations for medical, dental or toiletry purposes23%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations18%
C12NMicroorganisms or enzymes7%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms5%
G01NInvestigating or analysing materials by determining their chemical or physical properties4%
Y02ATechnologies for adaptation to climate change4%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests2%
A61FFilters implantable into blood vessels2%
A61LMethods or apparatus for sterilising materials or objects in general2%
PatentTitleYear
10,772,507Systems, devices and methods for monitoring breastfeeding202010,745,468Compositions and methods for modified B cells expressing reassigned biological agents202010,667,742Systems, devices and methods for monitoring breastfeeding202010,597,442Compositions and methods for modified B cells expressing reassigned biological agents202010,233,424Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin20199,956,106Gastrointestinal device with associated commensal microbes20189,949,855Gastrointestinal device with associated microbe-promoting agents20189,901,598'Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen'20189,845,351Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen20179,717,618'Gastrointestinal device with associated commensal microbes'20179,707,116'Gastrointestinal device with associated microbe-promoting agents'20179,681,615'Rapid breeding of plants'20179,662,354'Compositions, methods, and computer systems related to making and administering modified T cells'20179,649,185'Adjuncts for gastrointestinal devices'20179,637,540'Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen'20179,587,237'Compositions, methods, and computer systems related to making and administering modified T cells'20179,512,213'Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen'20169,499,855'Compositions, methods, and computer systems related to making and administering modified T cells'20169,468,655'Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen'20169,443,061'Devices and methods for recording information on a subject\'s body'20169,314,523'Ingestible salt grabber'20169,286,615'Devices and methods for recording information on a subject\'s body'20169,175,072'Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen'20158,962,315'Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen'20158,907,068'Anti-IL-20 antibodies and binding partners and methods of using in inflammation'20148,900,578'Anti-IL-TIF antibodies'20148,816,053'Methods for treating viral infection using IL-28 and IL-29 cysteine mutants'20148,536,309'Methods of producing anti-IL-22RA antibodies'20138,524,227'Anti-IL-TIF antibodies'20138,475,791'Anti-IL-TIF antibodies and methods of use'20138,361,954'Use of IL-28 and IL-29 to treat cancer and autoimmune disorders'20138,318,147'Use of IL-29 for treating a dengue virus infection'20128,287,866'Methods of treating IL-TIF associated inflammatory or immune diseases using antibodies against soluble zcytor 11 cytokine receptors'20128,283,448'Methods for treating viral infection using IL-28 and IL-29 cysteine mutants'20128,231,866'Cytokine protein family'20128,163,286'Anti-IL-22RA antibodies and binding partners and methods of using in inflammation'20128,154,285'Non-external static magnetic field imaging systems, devices, methods, and compositions'20128,124,077'Anti-IL-TIF antibodies and methods of making'20128,124,065'Cytokine Protein Family'20128,124,088'Methods of treatment using anti-IL-22RA antibodies'20128,106,655'Multiplex imaging systems, devices, methods, and compositions including ferromagnetic structures'20128,101,381'Human cytokine receptor'20128,063,636'Systems, devices, methods, and compositions including targeted ferromagnetic structures'20118,058,872'Systems, devices, methods, and compositions including functionalized ferromagnetic structures'20118,034,784'Method of suppressing or reducing IL-TIF-induced inflammation, or treating associated conditions thereof, using Zcytor16'20117,959,908'Methods of treating viral infections using IL-21'20117,923,208'Human cytokine receptor'20117,910,313'Cytokine protein family'20117,871,616'Anti-IL-22RA antibodies and binding partners and methods of using in inflammation'20117,851,594'Human cytokine receptor'20107,829,076'Method of using interferon-like potein ZCYTO20 (IL-28A) or ZCYTO22(IL-28B) to treat hepatitis B'20107,812,130'Human cytokine receptor'20107,790,851'Human cytokine receptor'20107,786,075'Use of IL-28 and IL-29 to treat cancer and autoimmune disorders'20107,718,172'Anti-IL-TIF antibodies and methods of using in inflammation'20107,674,461'Anti-IL-TIF antibodies'20107,667,000'Antibodies to Zcytor 16'20107,662,927'Antibodies to ZCYTO20 (IL-28A) and ZCYTO22 (IL-28B)'20107,655,222'Method of using interferon-like protein ZCYTO20 (IL-28A) or ZCYTO22 (IL-28B) to treat hepatitis C'20107,641,899'Methods for inhibiting IL-TIF-induced proliferation of hematopoietic cells using the cytokine receptor Zcytor16'20107,642,345'Polynucleotides encoding human cytokine receptor'20107,638,602'Human cytokine receptor'20097,615,611'Human cytokine receptor'20097,563,568'Method for detecting activated CD3+ T-cells'20097,537,761'Anti-IL-22RA antibodies and binding partners and methods of using in inflammation'20097,534,575'Method for detecting cancer using an antibody to Zcytor16'20097,491,809'Polynucleotides encoding human cytokine receptor'20097,485,699'Cytokine protein family'20097,462,467'Cytokine protein family'20087,455,993'Cytokine protein family'20087,446,172'Cytokine protein family'20087,445,773'Cytokine protein family'20087,393,684'Immunoconjugates of anti-IL-20 antibodies and hybridoma cell lines expressing anti-IL-20 antibodies'20087,351,555'Mouse cytokine receptor Zcytor16'20087,351,689'Use of IL-28 and IL-29 to treat cancer and autoimmune disorders'20087,265,203'Human cytokine receptor'20077,265,211'Anti-IL-TIF antibodies and methods of making'20077,189,839'Isolated polynucleotides encoding a human cytokine receptor human cytokine receptor'20077,135,170'Methods for treating viral infection using IL-28 and IL-29'20067,045,498'Soluble Zcytor11 cytokine receptors'20067,038,032'Cytokine protein family'20066,897,292'Human cytokine receptor'20056,875,845'Mouse cytokine receptor'20056,627,735'Islet cell antigen 1851'20036,544,505'Interferon-epsilon'20036,329,175'Interferon-.epsilon.'20016,323,323'Ligand-binding, dimerized polypeptide fusions'20016,300,099'Methods for producing secreted ligand-binding fusion proteins'20016,300,093'Islet cell antigen 1851'20016,291,646'Dimerized polypeptide fusions'20016,291,212'DNA constructs encoding ligand-binding fusion proteins'20016,060,309'Immune mediators and related methods'20006,018,026'Biologically active dimerized and multimerized polypeptide fusions'20005,919,635'Method of detecting glucagon receptor antagonists'19995,843,725'Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions'19985,776,725'Recombinant production of glucagon receptors'19985,770,445'Glucagon receptor proteins, peptides, and antibodies'19985,750,375'Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions'19985,567,584'Methods of using biologically active dimerized polypeptide fusions to detect PDGF'19965,155,027'Method of producing secreted receptor analogs and biologically active peptide dimers'19925,149,528'Cytotoxic protein from Trichosanthes kirilowii'19924,985,541'Novel cytotoxic protein'1991

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1991–2014Patents assigned to ZYMOGENETICS INC (69)· patent assignee history
1991–2020Based in Seattle, WA, US· patent location history
2011–2016Patents assigned to KINDSVOGEL WAYNE R (19)· patent assignee history
2011–2016Patents assigned to HYDE RODERICK A (9)· patent assignee history
2012–2014Patents assigned to SIVAKUMAR PALLAVUR V (7)· patent assignee history
2015–2020Patents assigned to ELWHA LLC (22)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ZYMOGENETICS INC691991–2014
ELWHA LLC222015–2020
KINDSVOGEL WAYNE Rself192011–2016
HYDE RODERICK A92011–2016
SIVAKUMAR PALLAVUR V72012–2014
Locations
LocationPatentsSpan
Seattle, Washington, US1021991–2020